AF
JNCE

Amalgamated Financial’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Amalgamated Financial’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$27K Buy
+3,986
New +$28.4K ﹤0.01% 2656

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Amalgamated Financial's JNCE Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022: 3,986 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #2656 among its holdings.

113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

  • Amalgamated Financial held 3,986 shares of Jounce Therapeutics, Inc. Common Stock worth $27K as of Q1 2022.
  • Jounce Therapeutics, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
  • Jounce Therapeutics, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2656 holding.
  • 113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.